The Psoriasis Stratification to Optimise Relevant Therapy (PSORT) consortium, prospectively recruited deeply-phenotyped discovery and refinement psoriasis patient cohorts, during the early phase of treatment with two distinct biologics, adalimumab (TNF inhibitor) and ustekinumab (IL-12/23 inhibitor)...
ORGANISM(S): Homo sapiens
